Skip to main content
Top
Published in: Pediatric Nephrology 3/2005

01-03-2005 | Original Article

Rapid development of glomerular injury and renal failure in mice lacking p53R2

Authors: David R. Powell, Urvi Desai, Mary Jean Sparks, Gwenn Hansen, Jason Gay, Jeff Schrick, Zheng-Zheng Shi, John Hicks, Peter Vogel

Published in: Pediatric Nephrology | Issue 3/2005

Login to get access

Abstract

The Rrm2b gene encodes p53R2, a catalytic subunit of ribonucleotide reductase that is required for DNA repair. Embryonic stem (ES) cells containing a retroviral insertion in the Rrm2b locus were used to generate mutant mice. Analysis of kidney RNA from Rrm2b (−/−) mice showed that the retroviral insertion disrupted expression of Rrm2b transcripts. Rrm2b (−/−) pups were represented at the expected Mendelian ratios at 10–12 days of age and grew normally past weaning. Mice failed to thrive after 6 weeks of age and began to die by 8 weeks of age. Phenotyping revealed that Rrm2b (−/−) mice died from a severe glomerular lesion that led to nephrotic syndrome and chronic renal failure. In kidneys of Rrm2b (−/−) mice, podocytes were enlarged and there was evidence of foot process effacement by 6 weeks of age. By 8 weeks of age, progressive podocyte hypertrophy and loss of foot processes was accompanied by hypertrophy of glomerular capillary endothelial cells that was extensive enough to restrict capillary blood flow. Collapsing glomerulopathy with avascular glomeruli was widespread in mice surviving beyond 9 weeks of age. Additional abnormalities in other organ systems were minor or consistent with secondary effects of renal failure. These findings suggest that lack of p53R2, the protein encoded by Rrm2b, has early and relatively selective detrimental effects on the kidney glomerulus that lead to rapid death from progressive renal failure.
Literature
1.
go back to reference Zambrowicz BP, Turner CA, Sands AT (2003) Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 3:563–570CrossRef Zambrowicz BP, Turner CA, Sands AT (2003) Predicting drug efficacy: knockouts model pipeline drugs of the pharmaceutical industry. Curr Opin Pharmacol 3:563–570CrossRef
2.
go back to reference Zambrowicz BP, Sands AT (2003) Knockouts model the 100 best-selling drugs—will they model the next 100? Nat Rev Drug Discov 2:38–51 Zambrowicz BP, Sands AT (2003) Knockouts model the 100 best-selling drugs—will they model the next 100? Nat Rev Drug Discov 2:38–51
3.
go back to reference Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT (1998) Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608–611CrossRef Zambrowicz BP, Friedrich GA, Buxton EC, Lilleberg SL, Person C, Sands AT (1998) Disruption and sequence identification of 2,000 genes in mouse embryonic stem cells. Nature 392:608–611CrossRef
4.
go back to reference Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A (2001) In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol 12:626–631 Walke DW, Han C, Shaw J, Wann E, Zambrowicz B, Sands A (2001) In vivo drug target discovery: identifying the best targets from the genome. Curr Opin Biotechnol 12:626–631
5.
go back to reference BeltrandelRio H, Kern F, Lanthorn T, Oravecz T, Piggott J, Powell D, Ramirez-Solis R, Sands AT, Zambrowicz B (in press) In: Carroll P (ed) Model organisms in drug discovery. Wiley & Sons, Chichester, UK BeltrandelRio H, Kern F, Lanthorn T, Oravecz T, Piggott J, Powell D, Ramirez-Solis R, Sands AT, Zambrowicz B (in press) In: Carroll P (ed) Model organisms in drug discovery. Wiley & Sons, Chichester, UK
6.
go back to reference Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP (2002) Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20:36–42CrossRef Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP (2002) Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 20:36–42CrossRef
7.
go back to reference Wattler S, Kelly M, Nehls M (1999) Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26:1150–1156, 1158, 1160 Wattler S, Kelly M, Nehls M (1999) Construction of gene targeting vectors from lambda KOS genomic libraries. Biotechniques 26:1150–1156, 1158, 1160
8.
go back to reference Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT (2003) Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100:14109–14114 Zambrowicz BP, Abuin A, Ramirez-Solis R, Richter LJ, Piggott J, BeltrandelRio H, Buxton EC, Edwards J, Finch RA, Friddle CJ, Gupta A, Hansen G, Hu Y, Huang W, Jaing C, Key BW Jr, Kipp P, Kohlhauff B, Ma ZQ, Markesich D, Payne R, Potter DG, Qian N, Shaw J, Schrick J, Shi ZZ, Sparks MJ, Van Sligtenhorst I, Vogel P, Walke W, Xu N, Zhu Q, Person C, Sands AT (2003) Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc Natl Acad Sci USA 100:14109–14114
9.
go back to reference Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42–49CrossRef Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y, Nakamura Y (2000) A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404:42–49CrossRef
10.
go back to reference Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647–40651CrossRef Guittet O, Hakansson P, Voevodskaya N, Fridd S, Graslund A, Arakawa H, Nakamura Y, Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647–40651CrossRef
11.
go back to reference Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34:440–445CrossRef Kimura T, Takeda S, Sagiya Y, Gotoh M, Nakamura Y, Arakawa H (2003) Impaired function of p53R2 in Rrm2b-null mice causes severe renal failure through attenuation of dNTP pools. Nat Genet 34:440–445CrossRef
12.
go back to reference Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR (2001) Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21:4829–4836CrossRef Donoviel DB, Freed DD, Vogel H, Potter DG, Hawkins E, Barrish JP, Mathur BN, Turner CA, Geske R, Montgomery CA, Starbuck M, Brandt M, Gupta A, Ramirez-Solis R, Zambrowicz BP, Powell DR (2001) Proteinuria and perinatal lethality in mice lacking NEPH1, a novel protein with homology to NEPHRIN. Mol Cell Biol 21:4829–4836CrossRef
13.
go back to reference Council NR (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC Council NR (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC
14.
go back to reference Tinsley FC, Taicher GZ, Heiman ML (2004) Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes Res 12:150–160 Tinsley FC, Taicher GZ, Heiman ML (2004) Evaluation of a quantitative magnetic resonance method for mouse whole body composition analysis. Obes Res 12:150–160
15.
go back to reference Silver J, Keerikatte V (1989) Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J Virol 63:1924–1928 Silver J, Keerikatte V (1989) Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus. J Virol 63:1924–1928
16.
go back to reference Benigni A, Remuzzi G (1996) Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 16:151–159 Benigni A, Remuzzi G (1996) Glomerular protein trafficking and progression of renal disease to terminal uremia. Semin Nephrol 16:151–159
17.
go back to reference Nagata M, Tomari S, Kanemoto K, Usui J, Lemley KV (2003) Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins. Pediatr Nephrol 18:3–8CrossRef Nagata M, Tomari S, Kanemoto K, Usui J, Lemley KV (2003) Podocytes, parietal cells, and glomerular pathology: the role of cell cycle proteins. Pediatr Nephrol 18:3–8CrossRef
18.
go back to reference Ghiggeri GM, Carraro M, Vincenti F (2004) Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 19:1036–1040CrossRef Ghiggeri GM, Carraro M, Vincenti F (2004) Recurrent focal glomerulosclerosis in the era of genetics of podocyte proteins: theory and therapy. Nephrol Dial Transplant 19:1036–1040CrossRef
19.
go back to reference D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43:368–382CrossRef D’Agati VD, Fogo AB, Bruijn JA, Jennette JC (2004) Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 43:368–382CrossRef
20.
go back to reference Stan RV, Tkachenko E, Niesman IR (2004) PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell 15:3615–3630CrossRef Stan RV, Tkachenko E, Niesman IR (2004) PV1 is a key structural component for the formation of the stomatal and fenestral diaphragms. Mol Biol Cell 15:3615–3630CrossRef
21.
go back to reference Stan RV, Ghitescu L, Jacobson BS, Palade GE (1999) Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J Cell Biol 145:1189–1198CrossRef Stan RV, Ghitescu L, Jacobson BS, Palade GE (1999) Isolation, cloning, and localization of rat PV-1, a novel endothelial caveolar protein. J Cell Biol 145:1189–1198CrossRef
22.
go back to reference Kriz W, Elger M, Mundel P, Lemley KV (1995) Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 5:1731–1739 Kriz W, Elger M, Mundel P, Lemley KV (1995) Structure-stabilizing forces in the glomerular tuft. J Am Soc Nephrol 5:1731–1739
23.
go back to reference Satchell SC, Anderson KL, Mathieson PW (2004) Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15:566–574 Satchell SC, Anderson KL, Mathieson PW (2004) Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15:566–574
24.
go back to reference Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9–15 Eremina V, Quaggin SE (2004) The role of VEGF-A in glomerular development and function. Curr Opin Nephrol Hypertens 13:9–15
25.
go back to reference Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716CrossRefPubMed Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N, Gerber HP, Kikkawa Y, Miner JH, Quaggin SE (2003) Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707–716CrossRefPubMed
26.
go back to reference Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369–2379 Roberts WG, Palade GE (1995) Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci 108:2369–2379
27.
go back to reference Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10:2440–2445PubMed Tryggvason K (1999) Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm. J Am Soc Nephrol 10:2440–2445PubMed
28.
go back to reference Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354CrossRefPubMed Boute N, Gribouval O, Roselli S, Benessy F, Lee H, Fuchshuber A, Dahan K, Gubler MC, Niaudet P, Antignac C (2000) NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 24:349–354CrossRefPubMed
29.
go back to reference Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256CrossRefPubMed Kaplan JM, Kim SH, North KN, Rennke H, Correia LA, Tong HQ, Mathis BJ, Rodriguez-Perez JC, Allen PG, Beggs AH, Pollak MR (2000) Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 24:251–256CrossRefPubMed
30.
go back to reference Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR (2004) Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2:E167 Yao J, Le TC, Kos CH, Henderson JM, Allen PG, Denker BM, Pollak MR (2004) Alpha-actinin-4-mediated FSGS: an inherited kidney disease caused by an aggregated and rapidly degraded cytoskeletal protein. PLoS Biol 2:E167
Metadata
Title
Rapid development of glomerular injury and renal failure in mice lacking p53R2
Authors
David R. Powell
Urvi Desai
Mary Jean Sparks
Gwenn Hansen
Jason Gay
Jeff Schrick
Zheng-Zheng Shi
John Hicks
Peter Vogel
Publication date
01-03-2005
Publisher
Springer-Verlag
Published in
Pediatric Nephrology / Issue 3/2005
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-004-1696-5

Other articles of this Issue 3/2005

Pediatric Nephrology 3/2005 Go to the issue